3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Endocrine
2
Thoracic
1
Sarcoma
1
Conditions
Neoplasms
3
Osteosarcoma
2
Triple Negative Breast Neoplasms
1
Sarcoma, Clear Cell
1
Sarcoma
1
Rhabdomyosarcoma
1
Pathologic Complete Response
1
Ovarian Carcinosarcoma
1
Neuroblastoma
1
Neoplasm Metastasis
1
Melanoma
1
Hodgkin Disease
1
Hepatoblastoma
1
Hemangiosarcoma
1
Glioblastoma
1
Fibrolamellar hepatocellular carcinoma
1
Ependymoma
1
Diffuse Intrinsic Pontine Glioma
1
Carcinoma, Neuroendocrine
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Adrenocortical Carcinoma
1
Interventions
tivozanib
1
repotrectinib
1
pembrolizumab
1
dostarlimab
1
atezolizumab
1
Fluorodeoxyglucose F18
1
Drug Therapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Neuroendocrine
×
dostarlimab
×
Sarcoma
×
Clear all
NCT06333314
2025-12-02
Pan-MSI-ACSE
UNICANCER
Phase 2
Recruiting
120 enrolled